"We need to focus on getting these drugs to patients quickly," expert says ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...

BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the ...

The oral presentation is titled “ The RAS:PI3Ka breaker BBO-10203 inhibits PI3Ka/AKT activity in HER2AMP models through non-canonical RAS signaling blockade .” A copy of the presentation will be ...

President Donald Trump said Tuesday he doesn't want to extend a rapidly expiring ceasefire in the U.S.-Israeli war on Iran ...

The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in patients with previously treated non-small cell lung cancer (NSCLC) whose ...

Researchers at the MRC Laboratory of Medical Sciences (LMS) and Imperial College London have identified an overworked cog in ...

'Self-fulfilling prophecies' aren't magic. They're specimens of Science, simplified.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of metabolic conditions such as obesity and diabetes. In addition to their weight loss benefits, these drugs also ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. We hypothesise that amylin ...